For: | Wu JY, Kang K, Yi J, Yang B. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. World J Clin Cases 2022; 10(18): 6110-6118 [PMID: 35949835 DOI: 10.12998/wjcc.v10.i18.6110] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i18/6110.htm |
Number | Citing Articles |
1 |
Yen T.H. Pham, Mai T. Vu, Anh Q. Nguyen, Phat N. Trinh, Mai H. Tran, Hieu C. Chu, Nguyet T.M. Nguyen, Chi H.V. Vu, Dinh V. Nguyen. Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer. Asia Pacific Allergy 2023; doi: 10.5415/apallergy.0000000000000131
|
2 |
|
3 |
Takashi K. Satoh, Matthias Munoz Neulinger, Pia‐Charlotte Stadler, Rui Aoki, Lars E. French. Immune checkpoint inhibitor‐induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications. The Journal of Dermatology 2024; 51(1): 3 doi: 10.1111/1346-8138.17039
|
4 |
Jia Zhou, Chuan-Peng Wang, Jun Li, Han-Lin Zhang, Chun-Xia He. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1414136
|